跳到主要內容

Morningside Venture Investments Ltd 的 Form 4/A 修正申報

修正

Amylyx Pharmaceuticals, Inc.(AMLX),2022/3/17 申報

申報編號
0000899243-22-011432
申報時間
2022/3/17 17:14 ET
交易日
2022/1/11
申報延遲
65 天
10b5-1 計畫
表單沒有這欄(2023 年以前)
原始申報日
2022/1/25

這份申報列了 2 筆非衍生性交易、4 筆衍生性交易。公開市場買進合計 $500.0 萬。交易後 65 天申報。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Morningside Venture Investments LtdCIK 0001543112持股 10% 以上大股東
Mvil, LLCCIK 0001914583持股 10% 以上大股東

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2022/1/11Common StockC轉換取得+10,415,650–F1–10,415,650間接重複申報
2022/1/11Common StockP買進取得+263,158$19.00+$5,000,00210,678,808間接重複申報

衍生性證券(表 II)

選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。

衍生性證券的交易
交易日證券交易標的股數單價金額交易後持有持有方式旗標
2022/1/11Common StockC轉換處分−1,409,035$0.00$00間接重複申報
2022/1/11Common StockC轉換處分−6,410,964$0.00$00間接重複申報
2022/1/11Common StockC轉換處分−974,107$0.00$00間接重複申報
2022/1/11Common StockC轉換處分−1,621,544$0.00$00間接重複申報

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F1

Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.

表 I 有 1 筆交易的價格引用這則附註。

F2

Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing Betty and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC.

F3

The shares of Series C-2 Preferred Stock and the Common Stock received upon conversion of the C-2 Preferred Stock are held by MVIL LLC.

備註

The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act.

看 SEC EDGAR 上的完整原文 (在新分頁開啟)